|
Abstract:
Enter a brief (approximately 200 words) We hypothesized that dehydroepiandrosterone metabolites or their synthetic derivatives are able to bind to the androgen receptor with low, if any, agonist activity and thus function as better antiandrogens than currently available ones. We previously identified three potential compounds with marginal androgenic activity. Using different prostate cancer cell lines, we evaluated the effects of these steroids on cell proliferation/apoptosis, cell migration/invasion, and the expression of several molecules related to cell growth/angiogenesis/metastasis. We found that these compounds indeed exhibited antiandrogenic activities, particularly on cell proliferation/apoptosis and prostate-specific antigen expression, although they were not always significant. Our results suggest that these compounds are superior to current antiandrogens, in terms of androgenic and antiandrogenic properties in prostate cancer cells in vitro. Tolerance of these compounds was also assessed in mice. The animals seemed to suffer from no adverse effects from injections of the steroids. We will next evaluate the anti-tumor effects of these compounds in mouse xenograft models for prostate cancer.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual summary rept. 1 Jul 2010-30 Jun 2011 |
| Pages: |
14 |
| Report Date: |
Jul 2011 |
| Contract Number: |
W81XWH-09-1-0305 |
| Report Number: |
A842945 |
|
|
|
|
|
Keywords relating to this report:
Email This Abstract
